Jin et al., 2019 - Google Patents
Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccinesJin et al., 2019
- Document ID
- 15746675042556047788
- Author
- Jin Z
- Gao S
- Cui X
- Sun D
- Zhao K
- Publication year
- Publication venue
- International journal of pharmaceutics
External Links
Snippet
Most pathogens enter the body through mucosal surfaces. Therefore, vaccination through the mucosal route can greatly enhance the mucosal immune response. Vaccination via the mucosal surface is the most effective way to trigger a protective mucosal immune response …
- 229960005486 vaccines 0 title abstract description 338
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines | |
| Ding et al. | Vaccine delivery systems toward lymph nodes | |
| Kehagia et al. | Advances in intranasal vaccine delivery: A promising non-invasive route of immunization | |
| Moyle | Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines | |
| Karch et al. | Vaccine technologies: From whole organisms to rationally designed protein assemblies | |
| JP2016539946A5 (en) | ||
| Rezaei et al. | Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials | |
| Chen et al. | Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects | |
| Wi et al. | Protective immunity against nervous necrosis virus in convict grouper Epinephelus septemfasciatus following vaccination with virus-like particles produced in yeast Saccharomyces cerevisiae | |
| Constantin et al. | Nano-carriers of COVID-19 vaccines: the main pillars of efficacy | |
| Shende et al. | Combined vaccines for prophylaxis of infectious conditions | |
| Depelsenaire et al. | Introduction to vaccines and vaccination | |
| JP2017537106A5 (en) | ||
| PH12020500194A1 (en) | Malaria vaccine | |
| CN104248754A (en) | Streptococcus suis vaccine composition, and preparation method and application thereof | |
| ECSP14023407A (en) | MODIFIED MAREK'S DISEASE VIRUS AND VACCINES MADE WITH IT | |
| WO2014185817A3 (en) | Vaccine for the prophylaxis and treatment of rotavirus infection with a fusion protein as active agent (variants) | |
| Mogilenko | Immunological Approaches Used in Vaccine Development | |
| Siddoway et al. | Equine Influenza Antigen-Based Particle Vaccine Protects Mice Against Homologous and Heterosubtypic Viral Challenges | |
| Teng Yap et al. | Navigating the horizon of mRNA vaccines: Tracing their evolution, ensuring safety, and unveiling therapeutic potential. | |
| Su | The Techniques Used on the Development of COVID-19 Vaccine | |
| 김낙원 et al. | Efficiency delivery of polyplex based on microneedle with enhancing immune response | |
| Amin | Studies on Antigenicity and Immunogenicity of Hepatitis A and Typhoid Vaccines | |
| Alishahi et al. | Serum antibody response of rainbow trout, Oncorhynchus mykiss to two species of pathogenic bacteria; Streptococcus iniae and Lactococcus garviae | |
| Petrovsky | Editorial (Thematic Issue: The Coming of Age of DNA Vaccines) |